Concepedia

Philip Komarnitsky

PK

26

Publications

2.4K

Citations

20

H-Index

1996

Active since

Affiliations

AbbVie (United States)(Current)

Harvard University

Duke Medical Center

AVEO Oncology (United States)

The University of Texas MD Anderson Cancer Center

Philip Komarnitsky is an author at AbbVie (United States) specializing in medicine, radiation oncology, and cancer therapeutics.

Top concepts

Publications per year

1996–2021

26

Publications

26

Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription

Philip Komarnitsky, Eun‐Jung Cho, Stephen Buratowski · Genes & Development · 2000 · 1.1K citations · Full text

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier et al. · Journal of Thoracic Oncology · 2021 · 239 citations · Full text

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland et al. · Journal of Thoracic Oncology · 2021 · 147 citations · Full text

Histone-like TAFs Are Essential for Transcription In Vivo

Bertha Michel, Philip Komarnitsky, Stephen Buratowski · Molecular Cell · 1998 · 98 citations · Full text

, , +8

ADR1 Activation Domains Contact the Histone Acetyltransferase GCN5 and the Core Transcriptional Factor TFIIB

Y. C. Chiang, Philip Komarnitsky, Dan Chase et al. · Journal of Biological Chemistry · 1996 · 85 citations · Full text

Rows per page

1–5 of 26